<DOC>
	<DOCNO>NCT01896388</DOCNO>
	<brief_summary>Accumulating evidence suggest key role N-methyl-D-aspartate ( NMDA ) receptor pathophysiology post-traumatic stress disorder ( PTSD ) . Recent study suggest NMDA receptor antagonist ifenprodil tartrate may potential therapeutic drug PTSD . The purpose study confirm whether ifenprodil tartrate effective treatment adolescent PTSD patient . If ifenprodil tartrate effective patient , study contributes development novel therapeutic drug PTSD .</brief_summary>
	<brief_title>Ifenprodil Tartrate Treatment Adolescents With Post-traumatic Stress Disorder : Double-blind , Placebo-controlled Trial</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Stress Disorders , Traumatic</mesh_term>
	<mesh_term>Stress Disorders , Post-Traumatic</mesh_term>
	<mesh_term>Ifenprodil</mesh_term>
	<criteria>[ Inclusion Criteria ] 1 . Diagnosis PTSD base DSMIVTR criterion . 2 . Score 25 high IESR . 3. currently outpatient Chiba University Hospital Department Psychiatry Child Psychiatry . 4. currently receive medication PTSD treatment follow medication : Antidepressants ( SSRI ; Fluvoxamine , Paroxetine , Sertraline , Escitalopram , SNRI ; Milnacipran , Duloxetine , NaSSa ; Mirtazapine ) , Mood stabilizer ( Lithium , Sodium Valproate , Carbamazepine , Lamotrigine ) , Atypical antipsychotic ( Risperidone , Olanzapine , Quetiapine , Perospirone , Aripiprazole , Blonanserin , Paliperidone ) . 5 . Ages 13 18 , male female 6. stable medication PTSD treatment may take previous 4 week prior enrollment study . 7 . Provision write informed consent patient parent guardian . 8. must able swallow powder medicine . [ Exclusion Criteria ] 1 . History allergic reaction hypersensitivity Ifenprodil Tartrate . 2 . Patients stop bleed intracranial hemorrhage . 3 . Patients informed disease time inform consent . 4 . Diagnosis follow disease base DSMIVTR criterion . Mental Retardation , Pervasive Developmental Disorders , AttentionDeficit / Hyperactivity Disorder , Schizophrenia Other Psychotic Disorders , Delirium , Dementia , Amnestic Other Cognitive Disorders , SubstanceRelated Disorders ( except CaffeineRelated Disorders , NicotineRelated Disorders ) . 5 . Somatic disorder require severe body management severe meal management . 6. receive treatment , antidepressant , mood stabilizer , atypical antipsychotic inclusion criterion # 4 , within 4 week prior enrollment study . 7. receive treatment follow NmethylDaspartate ( NMDA ) receptor antagonist : Ketamine hydrochloride , Amantadine hydrochloride , Memantine hydrochloride , dextromethorphan , Methadone ) within 4 week prior enrollment study . 8. pregnant nursing , intend become pregnant start breastfeeding study . 9. participate another clinical trial within 3 month prior enrollment study . ( except observation study without intervention ) . 10. plan change treatment unstable neurological manifestation somatic symptom . 11 . History suicidal ideation within past year . 12 . Other clinically significant reason exclusion investigator .</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>PTSD/ifenprodil</keyword>
</DOC>